| __timestamp | Ascendis Pharma A/S | Evotec SE |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 17990000 |
| Thursday, January 1, 2015 | 9415000 | 25166000 |
| Friday, January 1, 2016 | 11504000 | 27013000 |
| Sunday, January 1, 2017 | 13482000 | 42383000 |
| Monday, January 1, 2018 | 25057000 | 57012000 |
| Tuesday, January 1, 2019 | 48473000 | 66546000 |
| Wednesday, January 1, 2020 | 76669000 | 77238000 |
| Friday, January 1, 2021 | 160180000 | 105445000 |
| Saturday, January 1, 2022 | 221227000 | 156190000 |
| Sunday, January 1, 2023 | 264410000 | 169610000 |
| Monday, January 1, 2024 | 284545000 |
Cracking the code
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Ascendis Pharma A/S and Evotec SE, two prominent players in the industry, have shown distinct trends in their SG&A expenses over the past decade.
From 2014 to 2023, Ascendis Pharma A/S saw a staggering increase in SG&A expenses, growing by over 4,100%, from approximately $6.3 million to $264 million. In contrast, Evotec SE's expenses rose by about 840%, from $18 million to $170 million. This indicates that while both companies have expanded their operations, Ascendis Pharma A/S has experienced a more rapid increase in costs.
Understanding these trends can provide valuable insights into each company's strategic priorities and operational efficiencies, offering a glimpse into their future financial health.
Comparing SG&A Expenses: Merck & Co., Inc. vs Evotec SE Trends and Insights
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Evotec SE
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Who Generates More Revenue? Ascendis Pharma A/S or Evotec SE
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Ascendis Pharma A/S vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Evotec SE
Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Evotec SE
Celldex Therapeutics, Inc. or Evotec SE: Who Manages SG&A Costs Better?